We read with interest the article by Li *et al*. entitled "High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion" recently published in the European Respiratory Journal \[[@C1]\]. Although we do agree with the authors that high-flow nasal cannula (HFNC) might be an effective treatment for hypoxemic COVID-19 patients, we believe that caution should be taken in considering HFNC in COVID-19 patients as data about droplet dispersion and aerosol generation with HFNC are at least controversial \[[@C2]\]. The authors state that the scientific evidence of generation and dispersion of bio-aerosols *via* HFNC is similar to standard oxygen therapies. This statement is mainly based on the studies of Hui *et al*. \[[@C3]\] and Ip *et al*. \[[@C4]\] which showed that HFNC led to a smaller dispersion distance compared to non-rebreathing and Venturi masks during exhaled smoke dispersion experiments. The assumption that the *physical* extent of exhaled air plumes is equal to the *visible* extent of exhaled smoke plumes is wrong: the visibility of smoke rapidly decreases when it mixes with clean air, but smoke particles do not disappear. In addition to that, the dispersion of small-sized smoke particles and aerosols is not identical to the dispersion of particles that have a broad range of sizes. These observations are important when studying the actual spread of viruses.

When a jet escapes from the mask, nose, or mouth of a patient during ventilation therapy, virus-carrying droplets in the jet will follow different trajectories depending on their size. Each droplet of a specific size has a different terminal velocity (V~t~), *i.e.* the vertical velocity that will be reached in quiescent air. Larger droplets carrying viral parts have a relatively high terminal velocity and will therefore deposit sooner than smaller droplets \[[@C5]\], which was recently confirmed by Somsen *et al*. \[[@C6]\]. Patient-emitted aerosols however (droplet diameter\<1 μm), are excellent passive tracers just like smoke particles; they have very small terminal velocities and can end up anywhere before ultimately leaving through the ventilation system. They also may contain viral parts that may remain viable for at least 3 hours \[[@C7]\].

To estimate the dispersion of droplets, we have performed a passive-tracer visualisation using an anatomically correct 3D-printed head of a male adult, obtained from \[[@C8]\], which was modified with the author\'s permission. Normal breathing was simulated, and HFNC and oxygen therapies were applied. The lung simulator consisted of a P1D-S050MS-0320 pneumatic cylinder (Parker, Cleveland, USA) driven by a PS01-37Sx120F-HP-N rigidly connected linear motor (LinMot, Spreitenbach, Switzerland). The applied breathing pattern, mimicking healthy tidal breathing, had a tidal volume of 475 mL and a respiratory rate of 15·min^−1^. Smoke was generated using Miniax KS smoke patterns (Björnax AB, Nora, Sweden), consisting of particles between 0.3 and 2.5 μm, and inserted between the lung simulator and the 3D-printed head. The reflected light from the exhaled smoke was recorded using two camera\'s, and by combining these images, the extend of the exhaled air/smoke plumes was determined. From the distance and corresponding travelling time, air velocities during different therapies were estimated. Given the V~t~ of 25 cm·s^−1^ for droplets with a D~p~ of 100 µm (based on theory of \[[@C5]\]) and assuming a typical height of the patients nose compared to neighbouring surfaces of 10 cm, a rough estimate of the dispersion range of large (100 µm) droplets was obtained. The results are shown in [table 1](#TB1){ref-type="table"}.

###### 

Distances of exhaled smoke with visible concentration, velocities and estimated of dispersion range of large (100 µm) droplets under different conditions

  **Conditions**              **Dispersion distance of exhaled smoke at end-expiration (cm)**   **Calculated velocity at 0.5 s after start expiration (m/s)**   **Estimated dispersion range of large droplets (cm)**   
  --------------------------- ----------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------- ------
  Normal breathing            36.3                                                              0.46                                                            18.5                                                    
  HFNC, small size cannula    30 L·min^−1^                                                      71.2                                                            0.65                                                    26.2
  60 L·min^−1^                72.1                                                              0.83                                                            33.4                                                    
  HFNC, medium size cannula   30 L·min^−1^                                                      33.9                                                            0.64                                                    25.5
  60 L·min^−1^                48.5                                                              0.63                                                            25.4                                                    
  HFNC, large size cannula    30 L·min^−1^                                                      25.4                                                            0.47                                                    18.8
  60 L·min^−1^                73.3                                                              0.72                                                            28.8                                                    
  Nonrebreather mask          15 L·min^−1^                                                      20.3                                                            0.38                                                    15.1
  Venturi mask                FiO~2~ 0.4, 10 L·min^−1^                                          22.0                                                            0.23                                                    9.1
  FiO~2~ 0.6, 15 L·min^−1^    33.7                                                              0.26                                                            10.3                                                    

Dispersion distance of large droplets was estimated based on the air velocities at 0.5 s after start of expiration. Abbreviations: HFNC, high-flow nasal cannula; FiO~2~, fraction of inspired oxygen.

Our experiments show that the calculated air velocity during HFNC is larger than during oxygen therapies. Thus, also the estimated dispersion distance of large droplets is larger during HFNC compared to standard oxygen masks. Furthermore, the maximum range of visible smoke concentrations at the end of exhalation is larger during HFNC than during oxygen therapies, which contradicts the results of Hui *et al*. \[[@C3]\].

Due to the clear limitations of this relative simple experiment, the aim is not to provide exact distances and velocities, but rather to gain awareness for the increased velocity levels of exhaled air during HFNC compared to other oxygen therapies, especially at higher flow rates. This strongly suggests that larger droplets are more widely dispersed by HFNC therapy than by other oxygen therapies.

We do believe that HFNC can be considered as a therapy for COVID-19 patients, but, if applied, caution should be taken and adequate protective measures should be provided \[[@C9]\]. It is quite clear that further research on viral spread and risks associated with HFNC therapy in COVID-19 patients is mandatory.

**Data availability:** NA

Conflict of interest: Elshof reports grants from Vivisol BV, grants from Fisher and Paykel LtD, outside the submitted work;.

Conflict of interest: Ir. Hebbink reports grants and non-financial support from Fisher &amp; Paykel Healthcare, outside the submitted work;.

Conflict of interest: Dr. Duiverman reports grants from Philips BV, grants and personal fees from RESMED LtD, grants from Vivisol BV, grants from Fisher and Paykel LtD, outside the submitted work;.

Conflict of interest: Dr. Hagmeijer has nothing to disclose.
